Podcast brought to you by: Myraqa Clinical Research: The CRO for Point of Care and PMA Diagnostics.
And by: BioConference Live: Register for free to the upcoming online Clinical Diagnostics Conference May 29-31.
Alan Wright, MD, Chief Medical Officer, Roche Diagnostics Bio and Contact Info
Listen (9:05) Why do you think diagnostics are undervalued?
Listen (5:46) How are you going about raising the value for Dx?
Listen (8:20) Are the payers proving willing partners?
Listen (5:15) Society has two big decisions to make regarding Dx
Listen (2:53) How does patentability play into the difference between Rx and Dx?
There is an un-level playing field in the world of in vitro diagnostics. First of all, they are valued much lower than a therapeutic despite the amount of research and development that goes into refining a great diagnostic. Second, regulation is all over the board. A diagnostic may or may not be approved by the FDA. Something has to be done to level off this field if we are to see important innovation and the promise of personalized medicine fulfilled.
At least, that's the way our guest for today sees it. Alan Wright is the new Chief Medical Officer for Roche Diagnostics and he address an issue with which Roche has long been struggling. Alan is the former Chief Scientific officer for Caremark and so has a unique perspective from the developer and the payer's points of view. What is entailed in raising the value of diagnostics is the thrust of today's show.